Skip to content

Methotrexate in Retinal Detachment With Proliferative Vitreoretinopathy

Methotrexate as an Adjunct to Parsplana Vitrectomy for the Preventing and Treatment of Proliferative Vitreoretinopathy in Rhegmatogenous Retinal Detachment: A Clinical Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07058337
Acronym
Methotrexate
Enrollment
20
Registered
2025-07-10
Start date
2024-06-09
Completion date
2025-06-09
Last updated
2025-07-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal Detachment

Keywords

Proliferative Vitreoretinopathy, Rhegmatogenous Retinal Detachment, Methotrexate

Brief summary

The aim of this study is to evaluate the efficacy and safety of intraocular methotrexate (MTX) in preventing and managing proliferative vitreoretinopathy (PVR) in patients undergoing retinal detachment surgery

Detailed description

Patients will be randomized into two groups if clinical evidence of PVR is detected at the time of surgery, utilizing a computer-generated list for randomization. All surgeries will be conducted by the same surgeon to maintain consistency in technique. Intervention Groups: 1\. Group 1 (PPV Alone): Patients in this group will undergo pars plana vitrectomy (PPV) only. Group 2 (PPV with Methotrexate): Patients in this group will receive complete PPV along with adjunctive intravitreal methotrexate.

Interventions

23 gauge parsplana vitrectomy

PROCEDUREadjunctive use of Methotrexate

intravitreal methotrexate (200 μg/0.05 ml) at the time of surgery and repeated weekly for four weeks postoperatively

Sponsors

Benha University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 years and older. * Diagnosed with RRD with clinical signs of PVR. * No history of prior ocular surgeries for RRD or PVR.

Exclusion criteria

* Patients with other retinal diseases (e.g., diabetic retinopathy or retinal vascular occlusions). * Individuals with significant systemic illnesses that could influence surgical outcomes.

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity3 and 6 months after tamponade removalBest-Corrected Visual Acuity (BCVA): BCVA will be measured using the logarithm of the minimum angle of resolution (LogMAR) scale. A LogMAR value of 0.0 corresponds to normal visual acuity (Snellen equivalent 6/6 or 20/20), representing the ability to resolve an optotype that subtends 5 minutes of arc. Visual acuity will be converted to LogMAR values for statistical analysis.
Anatomical Successwithin 6 months after tamponade removalSuccessful Retinal Reattachment: Defined as complete reattachment of the neurosensory retina to the underlying retinal pigment epithelium (RPE) without persistent or recurrent subretinal fluid at the final follow-up visit, as confirmed by clinical examination and optical coherence tomography (OCT), in the absence of tamponade or additional surgical intervention.
Number of Operations Requiredwithin 6 months after tamponade removalThe total number of surgical procedures (including vitrectomy, scleral buckling, retinopexy, or tamponade exchange) required to achieve and maintain retinal reattachment will be recorded for each eye.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026